Loading
A phase 1/2 trial of Trifluridine/tipiracil, Bevacizumab in colorectal cancer, run by STCube, Inc., now recruiting.
Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer is a phase 1/2 interventional study registered as NCT06873763 by STCube, Inc., with 52 participants planned, started 2025-06-09 and due to reach its primary completion in 2025-12. Interventions recorded: Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab. Conditions listed: Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares STCube, Cytotoxic chemotherapy.
Shares Trifluridine/tipiracil, Anti-angiogenic therapy, Cytotoxic chemotherapy, Colorectal cancer.
Shares Trifluridine/tipiracil, Cytotoxic chemotherapy, Colorectal cancer.
Shares Trifluridine/tipiracil, Monoclonal antibodies, Cytotoxic chemotherapy.
Shares Trifluridine/tipiracil, Bevacizumab, Colorectal cancer.
Shares Trifluridine/tipiracil, Cytotoxic chemotherapy, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/